XTAI
3164
Market cap45mUSD
Oct 08, Last price
16.95TWD
1D
1.50%
1Q
3.04%
Jan 2017
-27.87%
IPO
8.51%
Name
GenMont Biotech Inc
Chart & performance
P/E
25.49
P/S
3.63
EPS
0.67
Div yield, %
4.72%
Shrs. gr., 5y
-3.76%
Rev. gr., 5y
4.29%
Revenues
401m
+4.11%
Net income
57m
-0.09%
CFO
74m
-40.62%
Dividend
Apr 08, 20260.8 TWD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Based in Taiwan, GenMont Biotech Incorporation is primarily engaged in the comprehensive process of developing, manufacturing, and marketing functional probiotic products. Beyond its core offerings, the company also provides specialized probiotic formulations. It extends its services to include original formula design and production for health-oriented food items, as well as supplying relevant manufacturing equipment. Additionally, GenMont Biotech actively collaborates on the research, production, and clinical evaluation of a variety of other products. The company was established in 2000 and has its headquarters situated in Tainan City, Taiwan.
Key people
Gende Chen
Chairman of the Board · since 2005
Weimin Chen
Chief Operating Officer · since 2020
Yujin Chen
Deputy General Manager · since 2020
Zhaotang Huang
Manager of Accounting · since 2023
Guojie Huang
Director · since 2014
Yixiong Lin
Director · since 2020
Dehui Yang
Director · since 2020
Chuanzhen Zhuo
Director · since 2020
Zhibin Gao
Independent Director · since 2020
Independent Director · since 2006
Qinglong Lin
Independent Director · since 2023
Jyh-Feng Lu
Independent Director · since 2006
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||